Vastra Tradgardsgatan 15
Stockholm 111 53
Sweden
46 86 15 20 40
https://www.oncopeptides.com/sv
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 63
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Jakob Lindberg Med. Lic | Chief Scientific Officer | 7,26M | N/D | 1972 |
Ms. Sofia Heigis M.Sc. | Chief Exec. Officer | N/D | N/D | 1980 |
Prof. Rolf Larsson M.D., Ph.D. | Founder | N/D | N/D | N/D |
Prof. Rolf Lewensohn M.D., Ph.D. | Founder | N/D | N/D | N/D |
Dr. Joachim Gullbo M.D., MSc Pharm, Ph.D. | Founder | N/D | N/D | N/D |
Dr. Kristina Luthman Ph.D. | Founder | N/D | N/D | N/D |
Prof. Hans Ehrsson M.D. | Founder | N/D | N/D | N/D |
Mr. Peter Nygren | Founder | N/D | N/D | 1959 |
Mr. Holger Lembrer M.Sc. | Chief Financial Officer | N/D | N/D | 1984 |
Mr. Henrik Bergentoft | Chief Financial Officer | N/D | N/D | 1974 |
Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is melflufen, a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
L'ISS Governance QualityScore di Oncopeptides AB (publ) al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.